---
title: "Key facts: ACRV ACR-368 ORR 39%; PD-1 combo P3 planned; Q1 loss $19M"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286380017.md"
description: "Acrivon (ACRV) Phase 2b ACR-368: overall ORR 39%; ORR 44% in ≤2 prior lines; ORR 52% in serous endometrial carcinoma ≤2 prior lines. Company added new study arms.1Acrivon (ACRV) showed preclinical synergy of ACR-368 and ACR-2316 with PD-1 and Topo1 inhibitors. Plans: Phase 3 for ACR-368 with PD-1, IND for CDK11 in H1 2027, AP3 programs in 20262Acrivon Therapeutics (ACRV) Q1 2026: operating loss $19.902M, operating expenses $19.902M, net loss $19.042M, basic loss per share $0.49.3"
datetime: "2026-05-14T07:55:34.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286380017.md)
  - [en](https://longbridge.com/en/news/286380017.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286380017.md)
---

# Key facts: ACRV ACR-368 ORR 39%; PD-1 combo P3 planned; Q1 loss $19M

-   Acrivon (ACRV) Phase 2b ACR-368: overall ORR 39%; ORR 44% in ≤2 prior lines; ORR 52% in serous endometrial carcinoma ≤2 prior lines. Company added new study arms.1
-   Acrivon (ACRV) showed preclinical synergy of ACR-368 and ACR-2316 with PD-1 and Topo1 inhibitors. Plans: Phase 3 for ACR-368 with PD-1, IND for CDK11 in H1 2027, AP3 programs in 20262
-   Acrivon Therapeutics (ACRV) Q1 2026: operating loss $19.902M, operating expenses $19.902M, net loss $19.042M, basic loss per share $0.49.3

### Related Stocks

- [ACRV.US](https://longbridge.com/en/quote/ACRV.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)

## Related News & Research

- [Acrivon Therapeutics, Inc. (ACRV) Receives a Buy from Oppenheimer](https://longbridge.com/en/news/286428001.md)
- [Enanta Pharma's RSV Bet And Immunology Ambitions](https://longbridge.com/en/news/286895623.md)
- [Erasca Touts 'Eye-Popping' ERAS-0015 Lung Cancer Data, FDA Path at BofA Conference](https://longbridge.com/en/news/286652404.md)
- [Bayer Granted Priority Review For Asundexian In Secondary Stroke Prevention](https://longbridge.com/en/news/286884841.md)
- [Relay's treatment shown to shrink vascular malformations in mid-stage trial](https://longbridge.com/en/news/286890329.md)